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Abstract
BACKGROUND: Cardiovascular disease (CVD) is one the cause of mortality in patients with type 1 diabetes (T1D). 
The development of CVD is mainly triggered by atherosclerosis, which is associated with the inflammatory process. 
AIM: The current study was aimed to investigate the association of Vitamin D level and premature atherosclerosis in 
adolescents with T1D, mainly through the regulation of various cytokines (interferon-γ [IFN-γ], IL-17, interleukin-10 
[IL-10], and transforming growth factor-β1 [TGF-β1]).
METHODS: This study was designed as a cross-sectional study involving 40 T1D and 40 healthy control who came 
to the outpatient clinic, Saiful Anwar Hospital, Malang, Indonesia, within the study period (January 2019-July 2019).
RESULTS: Our data demonstrated that the IFN-γ and IL-17 levels were significantly higher (p < 0.001), whereas 
the TGF-β1 and IL-10 levels were significantly lower (p < 0.001) in T1D group compared with control. Furthermore, 
T1D also has higher carotid intima-media thickness (cIMT) value and lower flow-mediated dilatation (FMD) value 
compared to the control group (p < 0.001). Level of 25(OH)D3 was strongly associated with reduced cIMT and 
elevated FMD (p < 0.005). The direct effect of 25(OH)D3 on cIMT and FMD was higher than the indirect effect of 
Vitamin D through TGF-β1, IL-10, IL-17, and IFN-γ. The cutoff value of 25(OH)D3 levels for the risk of atherosclerosis 
was 12.8 ng/dL (sensitivity 85.7% and specificity 86.7%).
CONCLUSION: The level of Vitamin D in the T1D group was significantly lower than those in healthy children and 
Vitamin D deficiency substantially influences the formation of premature atherosclerosis.
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Introduction
Type 1 diabetes (T1D) is caused by insulin 
deficiency and predominantly occurred in the pediatric 
population. International Diabetes Federation estimates 
as many as 1.1 million children and adolescents will be 
affected by T1D [1]. In Indonesia, the incidence of T1D 
was approximately 0.2–0.42 per 100.000 children in 2012 
[2]. The primary cause of mortality in T1D is cardiovascular 
disease (CVD) [3]. Evidence from the prospective study 
showed that T1D patients have a higher risk for the 
development of myocardial infarction, stroke, and heart 
failure compared to non-diabetic patients [4].
The increased risk of T1D-associated CVD 
cannot be described adequately by traditional risk 
factors (dyslipidemia, hypertension, smoking, and age) 
and microvascular complications, including nephropathy 
and neuropathy [2], [3], [4], [5], [6]. The possible 
explanation for CVD, particularly atherosclerosis, 
in patients with T1D might be linked to endothelial 
dysfunction, which is strongly associated with oscillating 
hyperglycemia and oxidative stress [3], [7], [8], [9]. 
Moreover, in T1D, absolute insulin deficiency also leads 
to elevated lipolytic activity, causes a release of 
pro-atherogenic lipoprotein (very low-density lipoprotein 
[LDL], intermediate-density lipoproteins, and LDL), 
and contributes to the development of atherosclerotic 
plaque [3], [10]. Subclinical atherosclerosis is defined 
as endothelial dysfunction, coronary calcification, and 
increased carotid intima-media thickness (cIMT) [11]. 
Increased cIMT and plaque formation are biologically 
and genetically distinct entities [12], [13]. A cIMT is a 
risk factor for cardiovascular events in addition to the 
other conventional vascular risk factors [13], [14]. Both 
calcified and non-calcified plaques are independent 
predictors of vascular disease for all age groups.
Increasing evidence supports a role for 
Vitamin D that extends beyond that of bone health [15]. 
Vitamin D deficiency is a known risk factor for CVD [16]. 
Low Vitamin D level in a patient with T1D is associated 
with future development of microalbuminuria, 
retinopathy, and coronary artery calcification as well as 
increased risk of all-cause mortality [17]. In addition, 
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Vitamin D deficiency has also been associated with 
the activation of the renin-angiotensin-aldosterone 
system and increased levels of inflammatory mediators 
resulting in target organ injury [18].
The balance between pro-inflammatory and 
anti-inflammatory cytokines is crucial in terms of both 
beta-pancreatic cell destruction and atherosclerotic 
plaque formation. Interferon-γ (IFN-γ) and 
interleukin-17 (IL-17) are secreted by Th1 and Th17 
subset, which associated with beta-cell destruction and 
pro-atherogenic, while IL-10 and transforming growth 
factor-β1 (TGF-β1) are anti-inflammatory cytokines 
which conversely inhibit beta-cell damage and plaque 
formation [19], [20]. Although some data are in favor 
of the role of Vitamin D in subclinical atherosclerosis, 
the association has not been settled yet. We aimed to 
evaluate the relationship between Vitamin D level and 
cIMT in patients with T1D through assessing the level 
of IFN-γ, IL-17, IL-10, and TGF-β1.
Subjects and Methods
Study design
This study was designed as a cross-sectional, 
which aimed to investigate the association of Vitamin D 
status with the level of various cytokines (IFN-γ, IL-17, 
IL-10, and TGF-β1) and the marker for premature 
atherosclerosis (cIMT and flow-mediated dilatation 
[FMD]). The procedures conducted in this study have 
been approved by the Research Ethical Committee, 
Faculty of Medicine, Universitas Brawijaya (No. 
400/214/k.3/302/2018). Research subjects were 
recruited using the consecutive sampling method, where 
each patient who met the inclusion criteria was included 
in the study from the period of January to July 2019 until 
the minimum sample size was achieved (40 subjects) 
based on the calculation of sample size as described 
in the literature [21]. All the children included in this 
study were subjected to general history taking, clinical, 
and laboratory assessment continued with specific 
examinations (cytokines and vitamin D level, cIMT, and 
FMD). This study was conducted at Policlinic of Pediatric 
Endocrinology, Saiful Anwar Hospital, Malang, Indonesia.
Inclusion criteria for the T1D group were 
defined as follows: has been diagnosed with T1D, aged 
10–18 years old, and the parents/guardian allowed 
him/her to be involved in this study after being given 
an explanation (informed consent). Exclusion criteria 
were defined as follows: Systemic infections, liver 
disorders, impaired kidney function, malignancy, and 
anemia (hemoglobin levels <11 g/dL, history of taking 
Vitamin D supplementation within the previous 3 weeks, 
amlodipine, valsartan, and statin treatment). For the 
control group, to rule out the diagnosis of T1D, we 
conducted a GAD65 assay. GAD65 assay was conducted 
by using an indirect enzyme-linked immunoabsorbent 
assay (ELISA) method, as previously described by 
literature [22]. Nutritional status was defined by plotting 
body mass index (BMI) into a standardized WHO chart 
for children aged 10–19 years old, then categorized as 
obese, overweight, normal, and underweight.
Measurement of cytokines and 25(OH)D3 
level
The level of cytokines was measured by ELISA 
methods as instructed by the manufacturer (IFN-γ, 
IL-17, IL-10, and TGF-β1; R&D systems). The level of 
25(OH)D3 was quantitatively measured by the ELISA kit 
produced by Cusabio (cat. CSB-E07900h). Briefly, after 
collecting 5 mL of whole blood within the EDTA-coated 
tube, the samples were then centrifuged for 2500 rpm 
for 15 minutes at room temperature. The supernatant 
then removed by using Pasteur pipettes into a new 
tube. The plasma samples then stored at -80°C to be 
analyzed together with the other samples.
ELISA method was performed after all the 
samples obtained. The reagents, standard dilutions, 
and samples were prepared at room temperature (RT). 
After adding 200 µL of assay diluent to each well, 100 
µL of standard, control, or sample were added into each 
well, covered with adhesive strip, then incubated at 
room temperature for two hours. Sequentially, 400 µL of 
washing buffer was added into each well and aspirated. 
This washing process was repeated four times. A 
100 µL of antibodies were added into each well, then 
incubated at RT for 30 minutes. The washing process 
then repeated for four times, continued with the addition 
of 100 µL of substrate solution and incubation period 
at RT for 30 minutes. Finally, 100 µL of stop solution 
was added into each well. The optical density (OD) of 
each plate was measured by using ELISA reader at 
the wavelength of 450 nm. The level of cytokines in 
each sample was derived from the standard curve. The 
procedure for 25(OH)D3 measurement is quite similar 
to the measurement of cytokines except the antibody 
were replaced by enzyme conjugate, and the OD was 
analyzed at the wavelength of 650 nm.
Measurement of cIMT
Analysis of cIMT was performed as previously 
described in the literature [23]. Briefly, the diameter of 
the left and right common carotid arteries were obtained 
from the M-mode picture of echocardiographic analysis 
(Philip Type 50G). This procedure was performed by a 
cardiologist. The measurement of carotid intima-media 
thickness (cIMT) was taken only from common carotid 
arteries (without internal carotid and carotid bulb) 
since it was technically feasible to be done in pediatric 
subjects. The premature atherosclerotic plaque was 
defined as cIMT of more than 0.5 mm.
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Measurement of FMD
FMD analysis was conducted to evaluate the 
function of the artery and has been done as previously 
described by the literature [24]. Briefly, the diameter of 
the brachial artery was measured while the position of the 
right arm was relaxed and supine so that the ultrasound 
examination is performed on the brachial artery 5–10 cm 
above the antecubital fossa. The cuff was inflated at supra 
systolic pressure (40–50 mmHg above systolic pressure) 
for 5 min; then sequentially, the cuff was quickly deflated 
and cause rapid blood flow. Arterial diameter is measured 
up to 5 min after the cuff was deflated, and the highest 
width is determined. Baseline diameter was defined as 
the diameter of the artery before the stimulation using 
an inflated sphygmomanometer cuff. The percentage 
of FMD is determined using a standardized formula as 
follows: FMD% = (peak diameter – baseline diameter)/
baseline diameter. While the peak diameter is the largest 
diameter after reactive hyperemia or after the cuff is 
suddenly deflated before returning to the base diameter, 
measured up to the 5th min after reactive hyperemia.
Statistical analysis
Statistical analysis was performed using SPSS 
for Windows software version 24.0. Patient demographic 
data, which includes age, sex, BMI, and laboratory 
examination results, are displayed in descriptive data. 
IL-10 and cIMT data were tested for normality (to 
determine the distribution of normal data or not) with 
Kolmogorov–Smirnov and variance homogeneity tests (to 
find out the same data variant or not). For the comparison 
study, if the variables were normally distributed and 
homogeneous, then the independent t-test was used. 
However, if the variables were not normally distributed 
and were not homogeneous, the Mann–Whitney test was 
used. Meanwhile, to see the correlation between IFN-
γ, IL-17, IL-10, TGF-β1 with cIMT, and FMD performed 
Pearson correlation test. A value of p < 0.05 indicates a 
statistically significant difference.
Results
Characteristics of research subjects
During the study period, we enrolled 80 
subjects consisting of 40 T1D patients and 40 healthy 
control. Briefly, there were no significant differences 
between diabetic and control groups based on age, 
gender, complete blood count parameters, renal 
function test, and C-reactive protein (CRP) level 
(p > 0.05). Moreover, the HbA1c level was significantly 
higher in the diabetic group compared with the control 
group (p < 0.001). Furthermore, lipid assay panels 
showed that the T1D group had a significantly higher 
LDL and total cholesterol level as compared to healthy 
subjects, but no difference was found in the TG and 
HDL levels. The characteristics of the subjects of this 
study are presented in Table 1.
Table 1: Characteristics of research subjects
Characteristic T1 diabetes (n=40) Control (n=40) p-value
Age (years) 14.62 ± 2.85 14.6 ± 0.98 0.236
Duration of diabetes (year) 4.75 ± 1.33 -
Gender
Male 17 (43%) 14 (35%) 0.453
Female 23 (57%) 26 (65%) 0.542
Hemoglobin (g/dL) 14.15 ± 1.11 14.57 ± 1.83 0.128
Leucocyte (103cells/ųL) 8.484 ± 2.789 7.529 ± 1.337 0.149
Thrombocyte (103 cells/ųL) 362.92 ± 62.49 346.12 ± 86.05 0.341
Urea (mg/dL) 23 ± 12 19.88 ± 5.2 0.315
Creatinine (mg/dL) 0.6 ± 0.4 0.64 ± 0.15 0.057
C-reactive protein (mg/dL) 0.14 ± 0.14 0.11 ± 0.22 0.056
Nutritional status
Normal 29 (72%) 34 (85%)
Underweight 7 (18%) 2 ( 5%)
Overweight 4 (10%) 4 (10%)
HbA1c (%) 9.55 ± 2.02 4.72 ± 0.24 <0.001*
<6.5% 3 (8%) 40 (100%)
≥6.5% 37 (92%) 0
Triglycerides (mg/dl) 107.5 ± 42.7 95.2 ± 45.01 0.087
Normal <90 mg/dl 38 (95%) 36 (90%)
High >150 mg/dl 2 (5%) 4 (10%)
Total cholesterol (mg/dl) 173.9 ± 36.8 132.5 ± 29.4 <0.001*
Normal <200 mg/dl 39 (98%) 39 (98%)
High >240 mg/dl 1 (2%) 1 (2%)
LDL (mg/dl) 127 ± 32 90.18 ± 25.34 <0.001*
Normal <100 mg/dl 33 (85%) 40 (100%)
High >160 mg/dl 6 (15%) 0
HDL (mg/dl) 56.3 ± 14.5 51.48 ± 10.78 0.100
Low <40 mg/dl 27 (68%) 37 (93%)
High >60 mg/dl 13 (32%) 3 (7%)
Data were presented as mean±SD, *p<0.05, which indicates significant.
Comparison of 25(OH)D3, premature 
atherosclerotic marker, and cytokines levels
Our data demonstrated that the level of 
25(OH)D3 in children with T1D was significantly lower as 
compared to the control group (p < 0.001). Furthermore, 
while the level of pro-inflammatory cytokines (IL-17 
and IFN-γ) was significantly elevated in the T1D group 
compared to the control group (p < 0.05), the level of 
anti-inflammatory cytokines were significantly reduced in 
T1D group compared with the control group (p < 0.001). 
The cIMT value in the T1D group was significantly higher 
compared to the control group (p < 0.001), suggesting 
that children with T1D have a higher susceptibility to 
develop CVD. In agreement with the structural defect as 
determined by cIMT, children with T1D have an impaired 
arterial function reflected by significantly lower FMD 
value compared to the control group (p < 0.001). The 
detail of these comparisons is presented in Table 2.
Table 2: Comparison of the level of Vitamin D, cytokines, cIMT, 
and FMD
Variable T1 diabetes (n=40) Control (n=40) p-value
Vitamin D (25[OH]D3) 10.41 ± 2.24 18.04 ± 1.41 <0.001*
Deficiency (<20 ng/ml) 37 (93%) 38 (95%)
Insufficiency (20–30 ng/ml) 3 (7%) 2 (5%)
Sufficiency (>30 ng/ml) 0 0
Cytokines levels
TGF-β1 (pg/mL) 39.83 ± 13.51 73.6 ± 15.34 <0.001*
IL-10 (pg/mL) 3.19 ± 0.85 9.39 ± 1.07 <0.001*
IL-17 (pg/mL) 4.89 ± 1.86 3.30 ± 0.56 <0.001*
IFN-γ (pg/mL) 26.06 ± 16.65 16.74 ± 7.20 0.001*
Atherosclerotic marker
cIMT (mm) 0.567 ± 0.87 0.387 ± 0.57 <0.001*
FMD (%) 7.17 ± 3.98 11.22 ± 5.48 <0.001*
Baseline diameter (mm) 2.86 ± 0.46 3.07 ± 0.44 <0.001*
Peak diameter (mm) 3.18 ± 0.46 3.65 ± 0.51 <0.001*
Data were presented as mean ± SD, *p<0.05 indicates significant. TGF-β1: Transforming growth factor-β1, 
IFN-γ: Interferon-γ, IL: Interleukin, FMD: Flow-mediated dilatation, cIMT: Carotid intima-media thickness.
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The relationship between T1D and 
premature atherosclerosis
Based on the Chi-square test, there was a 
significant relationship between the incidence of 
T1D with the incidence of atherosclerosis based 
on cIMT value (OR = 37,000; 95% CI = 9.3–146.6), 
indicating that patient with T1D has 37-fold higher 
risk to develop premature atherosclerosis compared 
to healthy control. The association analysis of type 1 
diabetes and premature atherosclerosis is shown in 
Table 4.
Table 4: The relationship between type 1 diabetes and 
premature atherosclerosis
Group Carotid intima-media thickness Total p-value
<0.5 mm (negative) >0.5 mm (positive)
Control 37 3 40 <0.001
Type 1 diabetes 10 30 40
Total 57 40 80
OR=37.000 CI 95%=9.335–146.651
Predictor variables of premature 
atherosclerosis
To investigate the predictor variables for 
the development of premature atherosclerosis, we 
performed logistic regression analysis on gender, 
age, duration of diabetes mellitus, lipid profile, 
HbA1c level, BMI, cytokines level, and 25(OH)D3 
level. Interestingly, a preliminary correlation study 
showed that gender, age, duration of diabetes 
mellitus, lipid profile, HbA1c level, and BMI did not 
significantly correlate with premature atherosclerosis 
(p > 0.05) (Table 5). However, the level of 25(OH)D3 
is significantly correlated with cIMT value (p < 0.001). 
Table 5: Correlation of subject characteristics and premature 
atherosclerosis
Correlation p r
cIMT and age 0.106 −0.260
cIMT and duration of DM 0.124 −0.247
cIMT and gender 0.653 −0.073
cIMT and BMI 0.890 0.023
cIMT and HbA1c 0.686 −0.066
cIMT and total cholesterol level 0.508 0.108
cIMT and LDL level 0.847 0.032
cIMT and HDL level 0.246 0.188
cIMT and TG level 0.658 −0.072
cIMT and 25(OH)D3 level <0.001 0.853
cIMT: Carotid intima-media thickness, BMI: Body mass index, HDL: High-density lipoprotein, LDL: Low-
density lipoprotein, TG: Triglyceride, DM: Diabetes mellitus.
Other variables, such as cytokines level (IL-17, IFN-γ, 
IL-10, and TGF-β1) and 25(OH)D3, were significantly 
correlated with premature atherosclerosis (p < 0.001). 
Surprisingly, logistic regression analysis by including 
the cytokines and 25(OH)D3 levels showed that these 
variables did not significantly influence premature 
atherosclerosis (Table 6).
Table 6: Predictor variables for premature atherosclerosis
Variables B SE Wald p OR 95% CI
25(OH)D3 0.863 1.377 0.393 0.531 2.370 0.2–35.2
IFN-γ 1.533 0.962 2.537 0.111 4.631 0.7–30.5
IL-10 -0.218 1.307 0.028 0.868 0.804 0.1–10.4
IL-17 0.959 1.631 0.346 0.556 2.610 0.1–63.8
TGF-β1 0.120 0.122 0.957 0.328 1.127 0.9–1.4
Constant −56.1 26.5 4.5 0.034 0.000
IFN-γ: Interferon-γ, IL: Interleukin, TGF-β1: Transforming growth factor-β1.
Correlation between 25(OH)D3 level and 
the cytokines level
To examine whether the Vitamin D status 
is associated with the balance between pro-
inflammatory and anti-inflammatory markers, we 
performed a correlation analysis. Our data revealed 
that the 25(OH)D3 level was positively associated with 
anti-inflammatory cytokines (IL-10 and TGF-β1). On 
the other hand, the 25(OH)D3 level was negatively 
correlated with pro-inflammatory cytokine (IL-17 and 
IFN-γ). This result indicates that Vitamin D modulates 
the inflammatory response through the attenuation of 
pro-inflammatory processes. The results of correlation 
analysis between vitamin D and cytokine levels is 
presented in Table 3.
Table 3: Correlation cytokines and Vitamin D level in type 1 
diabetes patients
Cytokine r p
IFN-γ −0.795 < 0.001
IL-17 −0.797 <0.001
IL-10 0.822 <0.001
TGF-β1 0.746 <0.001
TGF-β1: Transforming growth factor-β1, IFN-γ: Interferon-γ, IL: Interleukin.
Correlation between cytokines level and 
cIMT
To determine the association between 
atherosclerotic plaque formation and inflammatory 
processes, we conducted a correlation analysis. Our 
data demonstrated that cIMT is negatively correlated 
with IL-10 level (p < 0.001, r = −0.629) and TGF-β1 level 
(p < 0.001, r = −0.547). On the other hand, cIMT was 
positively correlated with IL-17 level (p < 0.001, r = 0.569) 
and IFN-γ level (p < 0.001, r = 0.650). These data 
suggest that the development of atherosclerosis plaque, 
particularly in the carotid arteries, is strongly associated 
with the inflammatory response. The graph presented 
the correlation between cytokine levels and cIMT value 
is shown in Figure 1.
Correlation between cytokines level and 
FMD
To investigate the association between 
inflammatory response and the function of the carotid 
artery, we performed a correlation study. Our data 
demonstrated that FMD was positively correlated 
with IL-10 level (p < 0.001, r = 0.635) and TGF-β1 
level (p < 0.001, r = 0.592). On the other hand, 
FMD was negatively correlated with IL-17 level 
(p < 0.001, r = −0.640) and IFN-γ level (p < 0.001, 
r = −0.655). Taken together with the cIMT data, these 
results indicate that pro-inflammatory cytokines 
have a positive impact on the stiffness of the artery, 
thus decreasing the FMD. The graph presented the 
correlation between cytokine levels and FMD value is 
shown in Figure 2.
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Receiver operating characteristic (ROC) 
analysis on the 25(OH)D3 level and premature 
atherosclerosis
ROC curve shows that the cutoff value for 
25(OH)D3 levels for the risk factor of premature 
atherosclerosis is 12.80 ng/dL. Based on the cut-
off value, 25(OH)D3 ≤ 12.80 ng/dL is categorized as 
a higher risk for the development or progression of 
premature atherosclerosis (sensitivity 85.7%, specificity 
86.7%, accuracy 86.3%, p < 0.001). The result of ROC 
analysis is shown in Figure 3.
Discussion
Our data demonstrated that the T1D group had 
a significantly higher level of LDL and total cholesterol, 
but no differences were found in the TG and HDL 
values. Quantitative lipoprotein abnormalities could 
be found in T1D patients with poor glycemic control 
(elevated plasma triglycerides and LDL cholesterol) 
or nephropathy (elevated triglycerides and LDL 
cholesterol, high-density lipoprotein levels). T1D with 
optimal glycemic control, plasma triglycerides, and LDL 
cholesterol are normal or slightly decreased, whereas 
HDL cholesterol is normal or slightly increased. Several 
qualitative abnormalities of lipoprotein, which are 
potentially atherogenic, were observed in patients with 
T1D, even with good metabolic control [25], [26].
The current study suggests that patients 
with T1D mellitus have significantly reduced 
Vitamin D levels, higher pro-inflammatory activity, and 
lower anti-inflammatory activity. These factors are 
possibly contributing to carotid stiffness and plaque 
deposition, as represented by elevated cIMT and 
reduced FMD. Correlation study also supports the 
notion that Vitamin D deficiency is strongly associated 
with the imbalance between pro-inflammatory and 
anti-inflammatory activity. Consequently, the profound 
activation of pro-inflammatory cells contributes to the 
development of atherosclerotic plaque.
In the diabetic state, a chronic inflammatory 
process is well-known as an important risk factor 
for β cell damage, insulin resistance, and diabetic 
Figure 1: Correlation between carotid intima-media thickness and pro-inflammatory or anti-inflammatory cytokines.
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vascular complications, endothelial dysfunction, 
and procoagulant imbalance [27], [28], [29]. An 
observational study demonstrated that T1D is an 
independent risk factor for increased carotid IMT in 
children [30], [31]. Inflammatory processes occur in 
atherosclerotic conditions characterized by increased 
CRP, pro-inflammatory cytokines, and decreased 
anti-inflammatory cytokines. The levels of hs-CRP, 
IL-6, IL-10 are independently related to the level of 
atherosclerosis [8], [32]. On the other hand, higher 
serum IL-10 levels are associated with a long-term risk 
of cardiovascular events [33].
Atherosclerosis is a chronic inflammatory 
disease of the arterial wall driven by innate and 
adaptive immune responses. Inflammation controls 
the development and the destabilization of arterial 
plaque. Cells involved in the atherosclerotic process 
secrete and are activated by soluble factors, known 
as cytokines. Important recent advances in the 
comprehension of the mechanisms of atherosclerosis 
have provided evidence for a dual role of cytokines: 
Pro-inflammatory and T helper-1-related cytokines 
promote the development and progression of the 
disease, whereas anti-inflammatory and regulatory 
T cell-related cytokines exert clear antiatherogenic 
activities [34], [35], [36].
Figure 2: Correlation between flow-mediated dilatation and pro-inflammatory or anti-inflammatory cytokines
Figure 3: Receiver operating characteristic analysis on 25(OH)D3 
level and the development of premature atherosclerosis
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Recent studies showed that several 
pro-atherogenic factors, including cholesterol, oxidized 
LDL, and fatty acids, regulate the production of IL-17 
and IL-17-promoting cytokines from innate and adaptive 
immune cells. Given that IL-17 is associated with a 
number of autoimmune diseases in humans, dissecting 
the mechanisms beyond the mutual regulation of 
pro-atherogenic factors and IL-17 might provide a 
novel pathophysiology between atherosclerosis and 
autoimmune diseases [37], [38]. The mechanism of 
protection appeared to be related to overt decreases in 
inflammation as levels of serum cytokines such as IL-6, 
IFN-γ, and IL-12 were reduced into the inflammatory 
process in atherosclerosis [39].
Vitamin D deficiency is related to enhance 
pro-inflammatory or autoimmune activity and 
atherosclerosis formation in T1D patients [40]. Low 
25-hydroxyvitamin D levels were associated with 
increased intima-media thickness and maximal 
carotid plaque thickness in those with plaque, and 
25-hydroxyvitamin D contributed in a robust manner to 
the variance in both. These results confirm and extend 
data on the association of low Vitamin D levels with 
subclinical carotid atherosclerosis [41], [42], [43], [44]. 
In addition, in advanced disease, there was a significant 
negative correlation between 25(OH)D and IL-17 in the 
diabetic neuropathy groups, suggesting that Vitamin D 
is a potentially modifiable risk factor for diabetes and 
may regulate inflammatory mediators, for example, 
IL-17 and IL-13 [45]. Clinically, Vitamin D levels were 
associated with HbA1c levels and IL-10 levels in 
T1DM [46]. An animal study also showed that 1,25-
(OH)2 D3 had a partially protective effect on diabetic 
rats, which might be through the inhibition of growth 
factors, VEGF, and TGF-β1 [47].
IL-10 plays a role in cardiac remodeling and 
has a protective effect on autoimmune diseases, one of 
which is T1D. In the process of atherosclerosis, IL-10 
can be both an agent that causes atherosclerosis and 
an atheroprotective agent [28], [29]. The functions of 
IL-10 are to control cell proliferation, cell migration, 
matrix synthesis, wound contraction, calcification, 
and immune response and all are major components 
of the atherosclerotic process. However, many of the 
effects of IL-10 are important for tissue repair; hence, 
IL-10 is also considered atheroprotective. The role of 
IL-10 in blood vessels is to inhibit the proliferation of 
endothelial and smooth muscle of blood vessels and 
play a role in tissue repair. Clinically, lower levels of 
IL-10 are correlated with atherosclerosis [48]. As the 
cIMT represents atherosclerosis, whereas IL-10 acts 
as an anti-atherosclerosis agent, the IL-10 level would 
be negatively correlated with cIMT [34], [49], [50]. In 
agreement with the previous studies, our data showed 
the same finding. Furthermore, our study showed that 
the TGF-β1 level was also negatively associated with 
cIMT. Conversely, a previous study demonstrated that 
elevated TGF-β levels in diabetes play a pathogenic 
role in the development of accelerated atherosclerosis 
in diabetes. Consequently, blocking growth factor 
actions on proteoglycan synthesis with many known 
cardiovascular and diabetes drugs attenuates lipid 
binding and potentially provides pleiotropic activities 
that assist in the prevention of atherosclerosis [51].
Our study showed important data regarding 
the relation of anti-inflammatory and pro-inflammatory 
cytokines and the development of premature 
atherosclerosis in children with type 1 diabetes. 
Nonetheless, because the current study was designed 
as a cross-sectional, it has less capability to explain the 
causative role of cytokine levels and plaque deposition. 
A prospective cohort might be required to address this 
highlighted issue. Furthermore, although the sample 
size has been fulfilled the minimum requirement for 
the statistical analysis, obtaining more subjects, or 
recruiting the subjects from different age groups might 
be beneficial to improve its clinical applicability.
Conclusions
We concluded that low Vitamin D levels 
are associated with premature atherosclerosis as 
determined by the elevation of intima-media thickness 
and the reduction of FMD of the common carotid 
artery. The pathogenesis of how Vitamin D affects the 
development of atherosclerosis might be related to the 
imbalance between pro-inflammatory (IL-17 and IFN-ϒ) 
and anti-inflammatory (TGF-β1 and IL-10) cytokines. 
Our data also suggests that T1D patient with Vitamin D 
level ≤12.80 ng/dL has a higher risk for the development 
of premature atherosclerosis.
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